Algenex
- Company typePrivate
- Founded2005
- HeadquartersPozuelo De Alarcón, Spain
- Headcount11–50
- GTM typeB2B
- OfferingServices
Algenex firmographics
Firmographics- Name
- Algenex
- Legal name
- ALTERNATIVE GENE EXPRESSION S.L.
- Website
- https://algenex.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Algenex industry classification
Industry- Product category
- Biotechnology - Recombinant Protein Production
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Vaccine Combination Products (Multivalent/Co-formulated) (HLAIAEAO), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
Keywords
Where Algenex is headquartered
LocationHeadquarters
- HQ city
- Pozuelo De Alarcón
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Algenex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Technology Licensing: Algenex licenses its proprietary CrisBio and TopBac technology platforms to pharmaceutical and diagnostic companies for product development and manufacturing. Partners include Fatro (vaccines), Virbac (swine vaccines), Biokit/Werfen (diagnostic kits).
- Contract Manufacturing Services: GMP-certified manufacturing services for active pharmaceutical substances using proprietary platforms. The company operates pharmaceutical-grade facilities in Madrid for production of biologics and vaccine antigens.
- Diagnostic Antigens and Products: Production and sale of recombinant antigen proteins for diagnostic and therapeutic markets including the Herdscreen ASFV antibody test developed with GlobalDX.
- Biocomponents: Supply of growth factors, enzymes, cytokines and other proteins for food technology applications including cultivated meat production, where growth media represents up to 95% of production costs.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Algenex product offering
Product offeringCore offering
Algenex develops and licenses proprietary baculovirus-based technology platforms (CrisBio® and TopBac®) for recombinant protein production using Trichoplusia ni insect chrysalis as natural bioreactors. The company provides contract manufacturing services for vaccine antigens, therapeutic proteins, and diagnostic antigens, and licenses its technology to pharmaceutical and diagnostic companies. Its products include the Herdscreen® ASFV rapid diagnostic test and recombinant antigens for vaccines and diagnostics.
Product overview
Algenex is a VC-backed Spanish biotech company that has developed two proprietary technology platforms for recombinant biologics production: TopBac® and CrisBio®. TopBac® is a patented baculovirus expression cassette that enhances recombinant protein yield and quality. CrisBio® is a disruptive manufacturing platform that uses Trichoplusia ni chrysalis as natural single-use bioreactors, achieving gram-per-litre productivity at low capital cost with linear scalability. The company applies these platforms across three strategic areas: Animal Health (veterinary vaccine development and manufacturing), Human Health (biotherapeutics and vaccine antigen production), and Diagnostics (antigens for serological tests). Algenex holds GMP certification from AEMPS for active pharmaceutical substance manufacturing and the CrisBio platform has received EMA validation. The company commercializes its own products (Herdscreen ASFV rapid diagnostic) and licenses its technology platforms to partners including FATRO, Virbac, and Biokit (Werfen). The 2022 acquisition by Insud Pharma Group integrated Algenex into a broader pharmaceutical group with global commercial reach across 50+ countries.
Differentiator
Problem solved
Functional benefit
Brands
- CrisBio: Proprietary baculovirus expression vector technology platform using chrysalis of Trichoplusia ni as living bioreactors for recombinant protein production. Offers gram-per-litre yields with linear scalability and reduced production costs.
- TopBac
- Herdscreen ASFV
Products and services
- CrisBio® Platform Baculovirus expression platform leveraging Trichoplusia ni chrysalis as living natural bioreactors for recombinant protein production. Automated process achieving gram-per-litre yields with extremely low capital investment and immediately scalable, flexible manufacturing. Licensed to pharmaceutical and diagnostic companies globally.
- TopBac® Expression Cassette Patented baculovirus expression cassette comprising multiple regulatory genetic elements working in cascade. When incorporated into a baculovirus genome, TopBac significantly enhances productivity and protein quality of recombinant proteins, and is fully compatible with common baculovirus-based production technologies.
- Herdscreen® ASFV Antibody Rapid Test Point-of-care rapid diagnostic test that identifies animals exposed to African Swine Fever Virus using whole blood, plasma, or serum samples, with 100% specificity and higher sensitivity than commercial ELISA tests. Antigen produced using the CrisBio platform. Developed jointly with GlobalDX.
- Recombinant Protein Production Services (CMO) GMP-certified production of active pharmaceutical substances for human and veterinary use, leveraging baculovirus-based expression platforms (CrisBio and TopBac) in insect cells. Services span vaccine antigen production, therapeutic proteins, growth factors, enzymes, cytokines, and diagnostic antigens.
- Biocomponents Production Services Production and supply of mammalian-free recombinant proteins and peptides at reduced cost, including growth factors, enzymes, and cytokines for industrial, therapeutic, and food technology applications including cultivated meat production.
Quantifiable outcome
- Productivity yields exceeding 1 gram per liter, significantly higher than alternative baculovirus approaches
- +3 more outcomes
Companies that use Algenex
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Algenex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Algenex partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- CEPIflagshipUp to $3.14 million funding for pre-clinical proof of concept study for influenza vaccine using CrisBio platform. Partnership supports 100 Days Mission to reduce vaccine development timelines. Includes commitment to equitable access and open-access publication of results.
- Fatro S.p.A.flagshipItalian veterinary pharmaceutical company. Commercial licensing agreement for FATROVAX RHD recombinant vaccine against Rabbit Hemorrhagic Disease produced using CrisBio technology. Marketing authorization received from European Commission and UK VMD in September 2021. Also developing second CrisBio-based vaccine.
- VirbaccoreInternational commercial licensing agreement for CrisBio-based vaccine in major swine indication. Vaccine to be jointly developed and manufactured using CrisBio technology.
- GlobalDXcoreJoint development and commercialization agreement for diagnostic products detecting African Swine Fever. Developed Herdscreen ASFV antibody test using antigen produced via CrisBio. Test commercialized since 2021 with 100% specificity.
- Biokit (Werfen Group)coreLicensed CrisBio technology to Biokit (part of Werfen Group) for commercializing recombinant proteins for in vitro diagnostic human use. Two diagnostic kits commercialized based on Algenex technology.
Scale indicators11 records
Recent moves9 records
Expansion highlights6 records
Algenex competitors and assessment
Company assessmentBroad incumbents
- Cobra Biologics (Charles River Laboratories): Specialist biologics CDMO (now part of Charles River) offering viral vector and recombinant protein services. Overlaps Algenex on biologics manufacturing services and vaccine antigens, but operates at significantly larger scale and broader scope.
- AGC Biologics: Global CDMO providing mammalian and microbial biologics manufacturing services, including vaccines and recombinant proteins. Competes for outsourced biologics production demand at much larger scale than Algenex.
- Thermo Fisher Scientific (Patheon/Bioservices): Global pharmaceutical services giant offering biologics CDMO services including cell-culture and viral vector production. Incumbent competitor with broader portfolio and substantially greater commercial reach.
- Boehringer Ingelheim BioXcellence: Large-scale biologics CDMO arm of Boehringer Ingelheim offering mammalian and microbial production. Competes broadly for vaccine/biologics contract manufacturing with deeper resources and longer track record.
Direct peers
- Biovian: Nordic GMP CDMO offering microbial and mammalian biologics manufacturing, including viral vector and vaccine production services. Comparable contract manufacturing and platform-based service offering.
- Kaneka Eurogentec: Belgian biologics manufacturer offering GMP plasmid DNA, recombinant proteins and vaccine antigen services. Comparable CDMO model focused on biologics and vaccine antigens.
- ProBioGen: German biologics CDMO specializing in insect cell/baculovirus-based protein production and viral vector manufacturing. Most directly comparable competitor in the same technology niche (insect-cell BVES) serving similar vaccine and gene therapy customers.
- Oxford Expression Technologies: UK-based specialist in baculovirus expression vector systems (flashBAC, BacPAK), licensing platform IP and offering related reagents/services. Competes head-to-head with CrisBio/TopBac for the same baculovirus-based recombinant protein customers.
- ExpreS2ion Biotechnologies: Denmark-based protein expression platform company offering proprietary Drosophila S2 cell-based recombinant protein production, including for vaccine antigens. Comparable platform-licensing + CDMO business model targeting vaccine developers.
Others
- Fatro S.p.A. Italian veterinary pharmaceutical company that is Algenex's flagship licensing partner for CrisBio-produced vaccines (FATROVAX RHD). Customer and co-developer rather than direct competitor, but a relevant comparable given shared veterinary vaccine exposure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Algenex social profiles
Digital presenceAlgenex compliance and trust
Trust signalCompliance2 records
Algenex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Algenex leadership team
Management profileNumber of profiles
Profiles8 records
Algenex funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Algenex M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Algenex
What does Algenex do?
Algenex develops and licenses proprietary baculovirus-based technology platforms (CrisBio® and TopBac®) for recombinant protein production using Trichoplusia ni insect chrysalis as natural bioreactors. The company provides contract manufacturing services for vaccine antigens, therapeutic proteins, and diagnostic antigens, and licenses its technology to pharmaceutical and diagnostic companies. Its products include the Herdscreen® ASFV rapid diagnostic test and recombinant antigens for vaccines and diagnostics.
Is Algenex a public or private company?
Algenex is a private company. It is classified as corporate owned and is currently operating.
When was Algenex founded?
Algenex was founded in 2005. It employs 11 to 50 people.
Where is Algenex based?
Algenex is headquartered in Pozuelo De Alarcón, Spain, in the Europe region.
How does Algenex make money?
Four revenue lines are on record. Technology Licensing is the primary driver. The others are contract Manufacturing Services, diagnostic Antigens and Products and biocomponents.
Who are Algenex's main competitors?
Broad incumbents on record are Cobra Biologics (Charles River Laboratories), AGC Biologics, Thermo Fisher Scientific (Patheon/Bioservices) and Boehringer Ingelheim BioXcellence. Direct peers are Biovian, Kaneka Eurogentec, ProBioGen, Oxford Expression Technologies and ExpreS2ion Biotechnologies. Fatro S.p.A. is listed as an others.
Does Algenex have an API?
No public API is recorded for Algenex.
What industry is Algenex in?
Algenex's product category is Biotechnology - Recombinant Protein Production. Its primary akta.pro industry code is HLAMAKAI, Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.